**Desert Angels have invested in over 100 companies and Calimmune is the largest investment ever made by the group.**
Calimmune Inc., a gene-therapy drug startup company co-founded by a University of Arizona alumnus, will be acquired by Australian-based biotech drug giant CSL Ltd. for $91 million.
The deal, which will make Calimmune part of Pennsylvania-based CSL Behring, also includes up to $325 million in potential performance based milestone payments over eight or more years after the transaction’s close, expected within the next two weeks.
Calimmune, co-founded by UA biology grad and entrepreneur Louis Breton in 2006, is developing stem-cell gene therapy to strengthen patients’ own immune systems.
Read full article here